Literature DB >> 29693328

American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus.

Hermine I Brunner1, Michael Holland1, Michael W Beresford2, Stacy P Ardoin3, Simone Appenzeller4, Clovis A Silva5, Francisco Flores1, Beatrice Goilav6, Scott E Wenderfer7, Deborah M Levy8, Angelo Ravelli9, Raju Khunchandani10, Tadej Avcin11, Marisa S Klein-Gitelman12, Brian M Feldman8, Nicolino Ruperto9, Jun Ying13.   

Abstract

OBJECTIVE: To validate the preliminary criteria of global flare for childhood-onset SLE (cSLE).
METHODS: Pediatricians experienced in cSLE care (n = 268) rated unique patient profiles; results of standard cSLE laboratory testing and information about the cSLE flare descriptors were presented as follows: global assessment of patient well-being, physician global assessment of disease activity (MD-global), Disease Activity Index score, protein/creatinine ratio (PCR), and erythrocyte sedimentation rate (ESR). Using rater interpretation of the course of cSLE (baseline versus followup as the gold standard), performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]) of the preliminary flare criteria was tested. An international consensus conference was held to rank the preliminary flare criteria as per the American College of Rheumatology recommendations and delineate threshold scores for minor, moderate, and major flares.
RESULTS: The accuracy of the 2 highest-ranked candidate criteria that consider absolute changes (∆) of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) or British Isles Lupus Assessment Group (BILAG) (numeric scoring: A = 12, B = 8, C = 1, and D/E = 0), MD-global, PCR, and ESR were confirmed (both AUC >0.93). For the SLEDAI-based criteria (0.5 × ∆SLEDAI + 0.45 × ∆PCR + 0.5 × ∆MD-global + 0.02 × ∆ESR) flare scores ≥6.4/3.0/0.6 constituted major/moderate/minor flares, respectively. For the BILAG-based algorithm (0.4 × ∆BILAG + 0.65 × ∆PCR + 0.5 × ∆MD-global + 0.02 × ∆ESR) flare scores ≥7.4/3.7/2.2 delineated major/moderator/minor flares, respectively. These threshold values (SLEDAI, BILAG) were all >82% sensitive and specific for capturing flare severity.
CONCLUSION: Provisional criteria for global flares in cSLE are available to identify patients who experienced a flare. These criteria also allow for discrimination of the severity of cSLE exacerbations.
© 2018, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29693328      PMCID: PMC5980747          DOI: 10.1002/acr.23557

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  27 in total

1.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

2.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors:  Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors:  L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal:  Arthritis Rheum       Date:  2012-01

5.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

6.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

7.  Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort.

Authors:  Louise Watson; Valentina Leone; Clarissa Pilkington; Kjell Tullus; Satyapal Rangaraj; Janet E McDonagh; Janet Gardner-Medwin; Nick Wilkinson; Phil Riley; Jane Tizard; Kate Armon; Manish D Sinha; Yiannis Ioannou; Neil Archer; Kathryn Bailey; Joyce Davidson; Eileen M Baildam; Gavin Cleary; Liza J McCann; Michael W Beresford
Journal:  Arthritis Rheum       Date:  2012-07

8.  How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.

Authors:  Maarten Boers; John R Kirwan; Laure Gossec; Philip G Conaghan; Maria-Antonietta D'Agostino; Clifton O Bingham; Peter M Brooks; Robert Landewé; Lyn March; Lee Simon; Jasvinder A Singh; Vibeke Strand; George A Wells; Peter Tugwell
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

9.  The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

Authors:  Nicolino Ruperto; Angelo Ravelli; Angela Pistorio; Virginia Ferriani; Immaculada Calvo; Gerd Ganser; Jurgen Brunner; Guenther Dannecker; Clovis Arthur Silva; Valda Stanevicha; Rebecca Ten Cate; Lisette W A van Suijlekom-Smit; Olga Voygioyka; Michel Fischbach; Ivan Foeldvari; Odete Hilario; Consuelo Modesto; Rotraud K Saurenmann; Marie-Josephe Sauvain; Iloite Scheibel; Danièle Sommelet; Lana Tambic-Bukovac; Roberto Barcellona; Riva Brik; Stephan Ehl; Mirjana Jovanovic; Jozef Rovensky; Francesca Bagnasco; Daniel J Lovell; Alberto Martini
Journal:  Arthritis Rheum       Date:  2008-01-15

10.  Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Dafna D Gladman; Dominique Ibañez; Murray D Urowitz; Earl D Silverman
Journal:  Arthritis Rheum       Date:  2008-02
View more
  4 in total

1.  American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Hermine I Brunner; Michael J Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Pinar Ozge Avar Aydin; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khubchandani; Tadej Avcin; Marisa S Klein-Gitelman; Nicolino Ruperto; Brian M Feldman; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-05       Impact factor: 4.794

2.  The cytoskeletal regulator HEM1 governs B cell development and prevents autoimmunity.

Authors:  Elisabeth Salzer; Samaneh Zoghi; Máté G Kiss; Frieda Kage; Christina Rashkova; Stephanie Stahnke; Matthias Haimel; René Platzer; Michael Caldera; Rico Chandra Ardy; Birgit Hoeger; Jana Block; David Medgyesi; Celine Sin; Sepideh Shahkarami; Renate Kain; Vahid Ziaee; Peter Hammerl; Christoph Bock; Jörg Menche; Loïc Dupré; Johannes B Huppa; Michael Sixt; Alexis Lomakin; Klemens Rottner; Christoph J Binder; Theresia E B Stradal; Nima Rezaei; Kaan Boztug
Journal:  Sci Immunol       Date:  2020-07-10

3.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

4.  International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis.

Authors:  Nathalie E Chalhoub; Scott E Wenderfer; Deborah M Levy; Kelly Rouster-Stevens; Amita Aggarwal; Sonia I Savani; Natasha M Ruth; Thaschawee Arkachaisri; Tingting Qiu; Angela Merritt; Karen Onel; Beatrice Goilav; Raju P Khubchandani; Jianghong Deng; Adriana R Fonseca; Stacy P Ardoin; Coziana Ciurtin; Ozgur Kasapcopur; Marija Jelusic; Adam M Huber; Seza Ozen; Marisa S Klein-Gitelman; Simone Appenzeller; André Cavalcanti; Lampros Fotis; Sern Chin Lim; Rodrigo M Silva; Julia Ramírez- Miramontes; Natalie L Rosenwasser; Claudia Saad-Magalhaes; Dieneke Schonenberg-Meinema; Christiaan Scott; Clovis A Silva; Sandra Enciso; Maria T Terreri; Alfonso-Ragnar Torres-Jimenez; Maria Trachana; Sulaiman M Al-Mayouf; Prasad Devarajan; Bin Huang; Hermine I Brunner
Journal:  Arthritis Rheumatol       Date:  2022-01-04       Impact factor: 10.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.